No abstract available.
Alopecia* ; Dutasteride* ; Finasteride*

PURPOSE: Finasteride is an inhibitor of human 5alpha-reductase, which results in a decrease in plasma and intraprostatic dihydrotestosterone(DHT) level. We investigated the changes of prostate volume(PV), transitional zone volume(TV), and PSA during and after administration of finasteride. MATERIALS AND METHODS: From 1995, 32 BPH patients treated with finasteride underwent surveillance after cessation of finasteride. Surveillance included measurements of PV, TV and PSA every 3 to 6 months. The mean age of the patients was 66.7 years(57-73). The mean duration of treatment and cessation were 8.6 months(6-12) and 8.0 months(6-12), respectively. The changes in PV, TV, and PSA were compared. RESULTS: The mean initial PV, TV, PSA were 45.7cc, 22.5cc, 2.72ng/ml, respectively. After treatment, PV, TV, PSA were reduced to 72.7%, 67.1%, 64.7% and 68.0%, 61.4%, 57.3% and 59.4%, 55.0%, 52.5% of the original values at 3, 6 and 12 months, respectively. The reduction rate was maximum after the first 3 months(p=0.001). After discontinuing finasteride, PV, TV, PSA recovered to 71.0%, 71.2% 63.9% and 84.0%, 82.3%, 67.6% and 90.4%, 85.1%, 74.1% at 3, 6 and 12 months, respectively. The recovery rates of PV and TV after 3 and 6 months were equal. However, recovery rate of PSA was maximum at 3 months and after then, constant until 12 months. CONCLUSIONS: During first 3 months` treatment, the decreasing rates of PV, TV and PSA were very considerable, after then, reduced. After cessation of medication the recovery rates of PV, TV were constant during first 6 months but PSA was maximum at first 3 months. The changes in clinical parameters during administration were fully recovered but it took slightly longer periods after cessation compared to those during of treatment. PSA is probably a predictor in the assessment of volume changes.
Finasteride* ; Humans ; Plasma ; Prostate*

No abstract available.
Animals ; Finasteride* ; Rats* ; Spermatogenesis*

No abstract available.
Finasteride* ; Risk Factors ; Venous Thrombosis*

No abstract available.
Animals ; Castration* ; Finasteride* ; Prostate* ; Rats*

No abstract available.
Female ; Finasteride ; Hair ; Humans ; Pilot Projects

Oral finasteride(Propecia(R)), 1mg/day, has been widely used as an effective treatment for male androgenetic alopecia since it had been approved by the Food and Drug Administration(FDA) of U.S. in December 1997. Gynecomastia has been one of the most common adverse effects in the patients who were taking 5mg of oral finasteride(Proscar(R)). Recently, several cases of unilateral or bilateral finasteride induced gynecomastia have also been reported in 1mg of oral finasteride(Propecia(r)). We report two cases of finasteride(Propecia(R)) induced painful bilateral gynecomastia, which are the first published documentations in Korea.
Alopecia ; Documentation ; Finasteride ; Gynecomastia* ; Humans ; Korea ; Male

PURPOSE: The aim of this study was to evaluate the efficacy of a combination drug therapy (tamsulosin plus finasteride) for benign prostatic hyperplasia, with a small prostate volume of less than 40 grams. MATERIALS AND METHODS: One hundred and twenty-three patients, with symptomatic benign prostatic hyperplasia of less than 40 grams, were analysed. Group 1 (n=67) had been treated with a combination of finasteride (5mg/day) and tamsulosin (0.2mg/ day), and Group 2 (n=56) with tamsulosin only (0.2mg/day) over a 12 month period. The patients were periodically assessed by IPSS (international prostate symptom score), uroflowmetry and residual urine, during the treatment period. RESULTS: The mean changes in the total symptom score, obstructive and irritative symptom score for group 1 and group 2 at 1 year were -7.21+/-7.44 (39.86%), -4.79+/-5.07 (45.02%) and -2.42+/-3.25 (48.11%), and -7.39+/-9.98 (43.06%), -4.82+/-6.91 (45.21%) and -2.39+/-4.00 (37.82%) points, respectively. The mean changes in the peak urinary-flow rates and postvoid residual urine for group 1 and group 2 at 1 year were 2.07+/-5.42 (16.65%)ml/s and -31.58+/-60.99 (56.47%)ml, and 2.38+/-6.57 (16.53%)ml/s and -34.78+/-86.77 (50.24%)ml, respectively. The effects of the combination of finasteride and tamsulosin were no greater than the tamsulosin monotherapy (p>0.01). CONCLUSIONS: A combination of finasteride and tamsulosin is no more effective than tamsulosin alone, in patients with benign prostatic hyperplasia, with a prostate volume of less than 40 grams.
Drug Therapy, Combination ; Finasteride* ; Humans ; Prostate* ; Prostatic Hyperplasia*

Finasteride, an inhibitor of type II 5alpha-reductase, inhibits conversion of testosterone to dihydrotestosterone (DHT), resulting in a decrease in serum and scalp DHT levels which are believed to be pathogenic in androgenic alopecia. Oral finasteride has been shown to be effective in the treatment of hair loss in men, while its efficacy in women has remained controversial. Herein, we report 10 cases of female patterned hair loss in postmenopausal women treated with 1 mg/day of finasteride.
Alopecia ; Dihydrotestosterone ; Female* ; Finasteride* ; Hair* ; Humans ; Male ; Scalp ; Testosterone

PURPOSE: Finasteride is being used as a medical therapy of benign prostatic hyperplasia (BPH), but there are no appropriate selection criteria for finasteride therapy. Our objective was to determine the usefulness of finasteride according to histological nature of the BPH, as determined by the transrectal ultrasonography (TRUS) findings. MATERIALS AND METHODS: Forty-two patients with symptomatic BPH were treated with finasteride (5mg/day) for more than 6 months. The patients were categorized into two groups of 21, according to their TRUS findings: the stromal, and the glandular, component dominant groups. The changes in prostate volume (PV), transition zone volume (TZV) and transition zone index (TZI) of each group, following at least 6 months of finasteride treatment, were evaluated and compared. RESULTS: In the stromal group the PV, TZV and TZI decreased from 69.3 11.5cc to 65.6 9.3cc, 43.5 13.2cc to 40.8 8.8cc and 0.63 to 0.62, respectively, but these changes were not statistically significant. While, in the glandular group, the PV, TZV and TZI decreased from 67.4+/-26.7cc to 56.2+/-25.2cc, 43.9+/-24.9cc to 32.4+/-19.9cc, and 0.63 to 0.54 (P<0.05), respectively. There was a linear correlation, only in the glandular group, between the TZI and TZV reductions following finasteride therapy (R=0.47, p=0.009). CONCLUSIONS: We suggest the prediction of the histological nature of BPH, by TRUS, would be helpful prior to the initiation finasteride treatment for effective reduction in the prostate volume with BPH. The effective reduction in the volume of the prostate in BPH would be possible only in glandular component dominant patients, as discriminated by TRUS.
Finasteride* ; Humans ; Patient Selection ; Prostate ; Prostatic Hyperplasia* ; Ultrasonography*